Skip to main content
padlock icon - secure page this page is secure

Correlation between Serum 25 hydroxy vitamin D level and plasminogen activator inhibitor 1 in type 2 diabetic patients

Buy Article:

$68.00 + tax (Refund Policy)

Introduction: It has been approved that vitamin D deficiency has a role in increasing the rate of cardio-vascular diseases in diabetic patients with unknown mechanism. The effects of vitamin D on hemostasis and its inflammatory mechanisms have been proposed as possible causes of cardio-vascular diseases in these patients. Also, high level of plasminogen activator inhibitor- type 1 (PAI-1) has been identified as a risk factor for cardio-vascular diseases in diabetic patients. The goal of this survey was to investigate the relation between vitamin D level and level of PAI-1 as a thrombotic marker.

Patients and Methods: 180 patients with type 2 diabetes mellitus enrolled for the study. The serum level of PAI-1 was measured by enzyme linked immune-assay and was compared with calcium metabolism markers including vitamin D, parathormon hormone, fasting blood sugar, calcium, and phosphorous.

Results: There was statistically significant relation between PAI-1 with fasting blood sugar and high density lipoprotein, but there was no significant relation between PAI-1 with vitamin D level and other cardio-vascular disease variables.

Discussion: It seems that serum level of vitamin D has no relation with PAI-1 in diabetic patients, although further investigations are required to confirm these findings.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Cardio-vascular diseases; diabetes; plasminogen activator inhibitor-type 1 (PAI-1); thrombosis; vitamin D level

Document Type: Research Article

Publication date: September 1, 2013

More about this publication?
  • This journal is devoted to timely reviews of experimental and clinical studies in the field of endocrine, metabolic, and immune disorders. Specific emphasis is placed on humoral and cellular targets for natural, synthetic, and genetically engineered drugs that enhance or impair endocrine, metabolic, and immune parameters and functions. Topics related to the neuroendocrine-immune axis are given special emphasis in view of the growing interest in stress-related, inflammatory, autoimmune, and degenerative disorders.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more